Cephalon Launches Takeover Bid For Australian Biotech Arana
This article was originally published in The Pink Sheet Daily
Executive Summary
Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.
You may also be interested in...
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
Mystery Shopper Arana Stops Trading On ASX Until “Take Over” Announced
PERTH, Australia - Aussie biotech Arana announced Feb. 26 that it has engaged in take-over discussions and halted trading on the Australian Stock Exchange in anticipation of the take over